Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Helix Kapital in connection with the fund formation of Helix Kapital Fund III
Mandate

Vinge has advised Helix Kapital in connection with the fund formation of Helix Kapital Fund III

April 05, 2024 Private Funds Corporate Tax

Vinge has advised Helix Kapital in the establishment of Helix Kapital’s third fund, Helix Kapital Fund III. The fund closed successfully with commitments of approximately SEK 1.5 billion from an international investor base consisting of a number of leading financial institutions. The investor interest in the fund raising was very strong, and the fund was significantly oversubscribed.

The fund will invest in tech-enabled businesses that specialize in the modernisation of traditional industries, by promoting industrial innovation, sustainable advancements and digital conversion.

Vinge’s team primarily consisted of Mattias Schömer, Martin Cronsioe, Emelie Svanberg, Semir Omerbasic, Viktoria Wnuk and Emelie Zingmark.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026